Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Wainberg, Zev A.Enzinger, Peter C.Kang, Yoon-KooYamaguchi, KenseiQin Shukui, Qin ShukuiLee, Keun-WookOh, Sang CheulLi Jin, Li JinTÜRK, HACI MEHMETTeixeira, Alexandra CarolinaCardellino, Giovanni GerardoGuardeno, RaquelMitra, SiddharthaYang Yingsi, Yang YingsiCollins, HelenCatenacci, Daniel V. T.2021-04-202021-04-202021-01-01Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021http://hdl.handle.net/20.500.12645/28794Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).ArticleWOS:00063671280019510.1200/jco.2021.39.3_suppl.160